X0609 4 2026-10-13 0 0001651308 BeOne Medicines Ltd. ONC 0001662982 Wang Xiaodong true C/O BEONE MEDICINES I GMBH AESCHENGRABEN 27, 21ST FLOOR BASEL V8 4051 SWITZERLAND 1 0 0 1 Chair, Scientific Advisory Brd 1 Ordinary Shares 4588113 D Ordinary Shares 1025063 I See Footnote Ordinary Shares 3953100 I See Footnote Ordinary Shares 50 I See Footnote American Depositary Shares 2026-10-13 4 M 0 31027 36.90 A 31027 D American Depositary Shares 2026-10-13 4 S 0 7167 349.5613 D 23860 D American Depositary Shares 2026-10-13 4 S 0 10361 350.4741 D 13499 D American Depositary Shares 2026-10-13 4 S 0 5681 351.3958 D 7818 D American Depositary Shares 2026-10-13 4 S 0 6558 352.5691 D 1260 D American Depositary Shares 2026-10-13 4 S 0 1260 353.2367 D 0 D Share Option (Right to Buy) 2.84 2026-10-13 4 M 0 403351 0 D 2026-11-15 Ordinary Shares 403351 403364 D These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interests are owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership. These securities are held by the spouse of the Reporting Person. Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.98 to $349.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $349.98 to $350.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.97, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.99 to $352.95, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.01 to $353.325, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 13, 2017, and the remaining in 36 successive equal monthly installments, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. /s/ Frank Collazo, as Attorney-in-Fact 2026-10-15